

EMA/414241/2024

European Medicines Agency decision P/0337/2024

of 13 September 2024

on the acceptance of a modification of an agreed paediatric investigation plan for cefiderocol (Fetcroja), (EMA-002133-PIP01-17-M04) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

Disclaimer

This decision does not constitute entitlement to the rewards and incentives referred to in Title V of Regulation (EC) No 1901/2006.

Only the English text is authentic.

European Medicines Agency decision

P/0337/2024

of 13 September 2024

on the acceptance of a modification of an agreed paediatric investigation plan for cefiderocol (Fetcroja), (EMA-002133-PIP01-17-M04) in accordance with Regulation (EC) No 1901/2006 of the European Parliament and of the Council

The European Medicines Agency,

Having regard to the Treaty on the Functioning of the European Union,

Having regard to Regulation (EC) No 1901/2006 of the European Parliament and of the Council of 12 December 2006 on medicinal products for paediatric use and amending Regulation (EEC) No. 1768/92, Directive 2001/20/EC, Directive 2001/83/EC and Regulation (EC) No 726/2004¹,

Having regard to Regulation (EC) No 726/2004 of the European Parliament and of the Council of 31 March 2004 laying down Union procedures for the authorisation and supervision of medicinal products for human use and establishing a European Medicines Agency²,

Having regard to the European Medicines Agency's decision P/0266/2018 issued on 14 August 2018, the decision P/0382/2020 issued on 18 September 2020, the decision P/0163/2022 issued on 13 May 2022 and the decision P/0441/2022 issued on 28 October 2022,

Having regard to the application submitted by Shionogi B.V. on 26 April 2024 under Article 22 of Regulation (EC) No 1901/2006 proposing changes to the agreed paediatric investigation plan with a deferral,

Having regard to the opinion of the Paediatric Committee of the European Medicines Agency, issued on 26 July 2024, in accordance with Article 22 of Regulation (EC) No 1901/2006,

Having regard to Article 25 of Regulation (EC) No 1901/2006,

Whereas:

- (1) The Paediatric Committee of the European Medicines Agency has given an opinion on the acceptance of changes to the agreed paediatric investigation plan and to the deferral.
- (2) It is therefore appropriate to adopt a decision on the acceptance of changes to the agreed paediatric investigation plan, including changes to the deferral.

¹ OJ L 378, 27.12.2006, p.1, as amended.

² OJ L 136, 30.4.2004, p. 1, as amended.

Has adopted this decision:

Article 1

Changes to the agreed paediatric investigation plan for cefiderocol (Fetcroja), powder for concentrate for solution for infusion, intravenous use, including changes to the deferral, are hereby accepted in the scope set out in the opinion of the Paediatric Committee of the European Medicines Agency annexed hereto, together with its appendices.

Article 2

This decision is addressed to Shionogi B.V., 33 Kingsway, Holborn, WC2B 6UF – London, United Kingdom.

EMA/PDCO/224204/2024
Amsterdam, 26 July 2024

Opinion of the Paediatric Committee on the acceptance of a modification of an agreed Paediatric Investigation Plan EMA-002133-PIP01-17-M04

Scope of the application

Active substance(s):

Cefiderocol

Invented name and authorisation status:

See Annex II

Condition(s):

Treatment of infections due to aerobic Gram-negative bacteria

Pharmaceutical form(s):

Powder for concentrate for solution for infusion

Route(s) of administration:

Intravenous use

Name/corporate name of the PIP applicant:

Shionogi B.V.

Basis for opinion

Pursuant to Article 22 of Regulation (EC) No 1901/2006 as amended, Shionogi B.V. submitted to the European Medicines Agency on 26 April 2024 an application for modification of the agreed paediatric investigation plan with a deferral as set out in the European Medicines Agency's decision P/0266/2018 issued on 14 August 2018, the decision P/0382/2020 issued on 18 September 2020, the decision P/0163/2022 issued on 13 May 2022 and the decision P/0441/2022 issued on 28 October 2022.

The application for modification proposed changes to the agreed paediatric investigation plan and to the deferral.

The procedure started on 27 May 2024.

Scope of the modification

Some timelines of the Paediatric Investigation Plan have been modified.

Opinion

1. The Paediatric Committee, having assessed the application in accordance with Article 22 of Regulation (EC) No 1901/2006 as amended, recommends as set out in the appended summary report:
 - to agree to changes to the paediatric investigation plan and to the deferral in the scope set out in the Annex I of this opinion.

The Paediatric Committee member of Norway agrees with the above-mentioned recommendation of the Paediatric Committee.

2. The measures and timelines of the paediatric investigation plan are set out in the Annex I.

This opinion is forwarded to the applicant and the Executive Director of the European Medicines Agency, together with its annexes and appendix.

Annex I

The subset(s) of the paediatric population and condition(s) covered by the waiver and the measures and timelines of the agreed paediatric investigation plan (PIP)

1. Waiver

Not applicable.

2. Paediatric investigation plan

2.1. Condition:

Treatment of infections due to aerobic Gram-negative bacteria

2.1.1. Indication(s) targeted by the PIP

Treatment of infections due to aerobic Gram-negative bacteria in paediatric patients with limited therapeutic options

2.1.2. Subset(s) of the paediatric population concerned by the paediatric development

From birth to less than 18 years of age

2.1.3. Pharmaceutical form(s)

Powder for concentrate for solution for infusion

2.1.4. Measures

Area	Description
Quality-related studies	Study 1: Generation of in-use stability data using water for injection, 5% dextrose and 0.45% sodium chloride injection as diluents for the powder for concentrate for solution for infusion.
Non-clinical studies	Study 2: 3-week subcutaneous and intravenous toxicity study of cefiderocol in juvenile rats. (S-649266-TF-274-L)
Clinical studies	Study 3: Open-label, single-arm, uncontrolled trial to evaluate safety, tolerability and pharmacokinetics of single and multiple doses of cefiderocol in hospitalised paediatric patients from 3 months to less than 18 years of age with suspected or confirmed infections due to aerobic Gram-negative bacteria. (1802R2135) Study 4: Open-label, single-arm, uncontrolled trial to evaluate safety, tolerability and pharmacokinetics of single and multiple doses of cefiderocol in hospitalised paediatric patients from birth to less than 3 months of age with suspected or confirmed infections due to aerobic Gram-negative bacteria. (1904R2136)
Extrapolation, modelling and simulation studies	Study 5: Modelling and simulation study to evaluate the use of cefiderocol for the treatment of children from birth to less than 18 years of age with suspected or confirmed infections due to aerobic Gram-negative bacteria.

	Study 6: Extrapolation study to evaluate the use of cefiderocol for the treatment of children from birth to less than 18 years of age with suspected or confirmed infections due to aerobic Gram-negative bacteria.
Other studies	Not applicable.
Other measures	Not applicable.

3. Follow-up, completion and deferral of PIP

Concerns on potential long term safety/efficacy issues in relation to paediatric use:	No
Date of completion of the paediatric investigation plan:	By May 2026
Deferral for one or more measures contained in the paediatric investigation plan:	Yes

Annex II

Information about the authorised medicinal product

Information provided by the applicant:

Condition(s) and authorised indication(s):

1. Treatment of infections due to aerobic Gram-negative bacteria

Authorised indication(s):

- Fetcroja is indicated for the treatment of infections due to aerobic Gram-negative organisms in adults with limited treatment options.
 - Invented name(s): Fetcroja
 - Authorised pharmaceutical form(s): Powder for concentrate for solution for infusion
 - Authorised route(s) of administration: Intravenous use
 - Authorised via centralised procedure